Wednesday, Nov 29, 2023
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Education Today
    • Reviews
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | India | 84 Yr Old Haryana Man First In India To Get Antibody Cocktail

84-yr-old Haryana man, first in India to get antibody cocktail

Mohabbat Singh, who was under treatment for the last five days at Gurugram's Medanta Hospital was on Tuesday given the drug over a 30 minute intravenous supply.

By ANI
Published Date - 04:54 PM, Wed - 26 May 21
84-yr-old Haryana man, first in India to get antibody cocktail
Mohabbat Singh, 84-year-old from Haryana. Source: Twitter
whatsapp facebook twitter telegram

Gurugram: An 84-year-old man from Haryana has become the first person in India to be administered the Covid drug cocktail, which came into limelight after it was administered to former US President Donald Trump when he tested positive for the virus last year.

Mohabbat Singh, who was under treatment for the last five days at Gurugram’s Medanta Hospital was on Tuesday given the drug over a 30 minute intravenous supply.


The cocktail of two fast acting antibodies-Casirivimab and Imdevimab is seen as a cutting-edge treatment that will provide protection to Covid-19 patients with mild and moderate symptoms before their condition deteriorates and they require hospitalization.

The first batch of the Roche antibody cocktail drug arrived in the country on Monday, according to an official announcement by Roche India and Cipla Limited.

“If these antibodies are injected into a patient infected with the Covid-19 virus at an early stage when the virus is trying to multiply then it blocks the virus from entering the cells of the patient from where it derives nutrition to multiply. So by blocking the virus they are stopping the multiplication of the virus and finally the virus spikes. It is one of the blocking mechanisms that is working against the Covid-19 virus,” Doctor Naresh Trehan, Chairman and MD of Medanta hospital told ANI.

Dr Tehran further said that the antibodies are also effective against the new variant B.1.617.2 and this has been verified in laboratories as well.

The antibody cocktail therapy is not recommended for patients who are hospitalized due to severe Covid-19, or those who require oxygen therapy due to Covid-19 or who require an increase in baseline oxygen flow rate due to Covid-19 and in patients on chronic oxygen therapy due to underlying non-Covid-19 related comorbidity.

“It has been tested and used extensively in the US and Europe and the experience shows that (it works) when given timely, that means the first seven days of viral replication stage or when the virus multiplies. So, by blocking it then you are reducing the severity of the disease in everybody, but also in those who had a severe infection because of comorbidities along with their age and also a high viral load. It has been found effective when given on time, the sooner you give it more effective it is,” Dr Trehan said.

This FDA-approved therapy demonstrated good efficacy in Phase 1/2 and Phase 3 studies by reducing Covid-19 related hospitalization and death by 70 per cent. Approved by the Drugs Controller General of India (DCGI), this single dose infusion-based treatment can be provided on an outpatient or daycare basis and marks a dramatic shift in Covid-19 care in India.

“We are glad to now have access to Monoclonal Antibody Therapy in India. This fast and effective treatment for COVID -19 will save patients at the highest risk from falling critically ill, getting hospitalized or possibly dying of complications from Covid-19. We look forward to serving our patients with this therapy and saving more lives,” said Dr Naresh Trehan.

The doctor, however, said that patients are advised to check with their doctor if monoclonal antibody therapy may be beneficial to them in the treatment of their Covid-19 infection.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • 84-year-old man
  • antibody cocktail
  • Mohabbat Singh
  • Roche antibody cocktail drug

Related News

  • FBI searches Trump’s Florida home

    FBI searches Trump’s Florida home

  • Iran calls nuke deal parties for immediate ‘political decisions’ in talks

    Iran calls nuke deal parties for immediate ‘political decisions’ in talks

  • Modi’s ‘Abki baar Trump sarkar’ a Himalayan blunder: KCR

    Modi’s ‘Abki baar Trump sarkar’ a Himalayan blunder: KCR

  • Yashoda Hospitals launches antibody cocktail drugs to treat Covid

    Yashoda Hospitals launches antibody cocktail drugs to treat Covid

  • Google removes Trump’s campaign app from Play Store

    Google removes Trump’s campaign app from Play Store

  • Britain to host first G7 summit of Biden era in June

    Britain to host first G7 summit of Biden era in June

Latest News

  • Rahul Dravid to continue as ‘Team India’ head coach

    4 mins ago
  • Telangana Assembly polls: Fake Intelligence Bureau prediction goes viral

    25 mins ago
  • 40 passengers fall ill due to food poisoning on Bharat Gaurav train

    35 mins ago
  • How Safe are Cough Syrups for Diabetes?

    43 mins ago
  • Gold prices soar to 7-month high

    1 hour ago
  • Kerala and Wayanad are like home to me, says Rahul Gandhi

    1 hour ago
  • Telangana Elections: BJP Offers Free Gas Cylinders, 1 Percent Interest Loans, Corruption Free State

    2 hours ago
  • Hrithik Roshan, Jr NTR starrer ‘War 2’ to release on this date

    2 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam